Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)

MLA

Xiaobin Shang, et al. “Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002).” Frontiers in Oncology, vol. 12, Mar. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.831345.

APA

Xiaobin Shang, Wencheng Zhang, Gang Zhao, Fei Liang, Chen Zhang, Jie Yue, Xiaofeng Duan, Zhao Ma, Chuangui Chen, Qingsong Pang, Weihong Zhang, Liang Liu, Xiubao Ren, Bin Meng, Peng Zhang, Yegang Ma, Lin Zhang, Hecheng Li, Xiaozheng Kang, … Hongjing Jiang. (2022). Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.831345

Chicago

Xiaobin Shang, Wencheng Zhang, Gang Zhao, Fei Liang, Chen Zhang, Jie Yue, Xiaofeng Duan, et al. 2022. “Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002).” Frontiers in Oncology 12 (March). doi:10.3389/fonc.2022.831345.